InvestorsHub Logo
Followers 826
Posts 119062
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 820

Wednesday, 06/22/2022 7:22:56 AM

Wednesday, June 22, 2022 7:22:56 AM

Post# of 864
FDA approves MRK’s pneumococcal vaccine, Vaxneuvance for infants/children:

Vaxneuvance was already FDA-approved for adults (#msg-164961310), but I don’t think Vaxneuvance will compete effectively with PFE’s Prevnar-20, which has broader coverage of pneumococcal serotypes and a simpler (one-shot) treatment course (#msg-166441188).

PFE's Prevnar-20 is FDA approved for adults, but is not yet approved for infants/children, so MRK does have a head start in the pediatric market.

MRK pays PFE a royalty of 7.25% on worldwide Vaxneuvance sales during 2022-2026 and a 2.5% royalty during 2027-2035 (#msg-166075692).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News